Focused Ultrasound
DeviceDIADEM device
NCT Number: NCT07226648
The goal of this clinical trial is to evaluate a new noninvasive brain stimulation intervention for fibromyalgia and to determine its effectiveness in reducing pain. Participants will receive four treatments over the course of one month and will complete surveys at multiple time points throughout the 16-week study.
Interested in participating?
Request Info22 year and older
All sexes
Interventional
Not applicable
University of Michigan, Ann Arbor, Michigan, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DIADEM device
Time frame: 28 days following initial treatment
The NRS-11 is a scale from 0-10 with higher values representing higher levels of pain.
Time frame: 28 days following initial treatment
The FIQR is a scale ranging from 0 to 100 that evaluates function, overall impact, and symptoms of fibromyalgia over the past 7 days. Higher scores represent more severe impact to the patient.
Time frame: 28 days following initial treatment
≥ 30% reduction from baseline in NRS-11 score (the NRS-11 is a scale from 0-10 with higher values representing higher levels of pain).
Time frame: 28 days following initial treatment
The PROMIS-29 is a 29 question survey assessing physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, and pain intensity. The Pain Interference Subscale is scored on a 5 point scale and asks how much pain interfered with different activities (1 - Not at all; 2 - A little bit; 3 - Somewhat; 4 - Quite a bit; 5 - Very much). Scores are calculated as T-scores with a mean of 50 and a standard deviation of 10. Higher scores represent more pain interference.
Time frame: 7 days following initial treatment
≥ 30% reduction from baseline in NRS-11 score (the NRS-11 is a scale from 0-10 with higher values representing higher levels of pain).
Time frame: 28 days following initial treatment
The PGI-I is a scale from 1-7 indicating how the patient has felt overall since beginning treatment. 1 - Very Much Improved; 2 - Much Improved; 3 - Minimally Improved; 4 - No Change; 5 - Minimally Worse; 6 - Much Worse; 7 - Very Much Worse.
Time frame: 28 days following initial treatment
The PHQ-9 is a 9-question survey asking "Over the last 2 weeks, how often have you been bothered by any of the following problems?" Each question is scored as:
0: Not at all;
Time frame: 16 weeks following initial treatment
The NRS-11 is a scale from 0-10 with higher values representing higher levels of pain.
Time frame: 28 days following initial treatment
The PROMIS-29 is a 29 question survey assessing physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, and pain intensity. Scores for subscales are calculated as T-scores with a mean of 50 and a standard deviation of 10. Higher scores represent worse health than average for anxiety, depression, fatigue, sleep disturbance, and pain interference. Higher scores represent better health than average for physical function and ability to participate in social roles and activities.
Time frame: 28 days following initial treatment
The BPI includes questions on a scale from 0-10 with higher values representing higher levels of pain or higher levels of pain interference.
Time frame: 16 weeks following initial treatment
The FIQR is a scale ranging from 0 to 100 that evaluates function, overall impact, and symptoms of fibromyalgia over the past 7 days. Higher scores represent more severe impact to the patient.
Time frame: 16 weeks following initial treatment
The PROMIS-29 is a 29 question survey assessing physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, and pain intensity. Scores for subscales are calculated as T-scores with a mean of 50 and a standard deviation of 10. Higher scores represent worse health than average for anxiety, depression, fatigue, sleep disturbance, and pain interference. Higher scores represent better health than average for physical function and ability to participate in social roles and activities.
Time frame: 16 weeks following initial treatment
The PHQ-9 is a 9-question survey asking "Over the last 2 weeks, how often have you been bothered by any of the following problems?" Each question is scored as:
0: Not at all;
Time frame: 16 weeks following initial treatment
The PGI-I is a scale from 1-7 indicating how the patient has felt overall since beginning treatment. 1 - Very Much Improved; 2 - Much Improved; 3 - Minimally Improved; 4 - No Change; 5 - Minimally Worse; 6 - Much Worse; 7 - Very Much Worse.
Time frame: 16 weeks following initial treatment
The BPI includes questions on a scale from 0-10 with higher values representing higher levels of pain or higher levels of pain interference.
Time frame: Through 28 days following initial treatment
Time frame: Through 16 weeks following initial treatment
Time frame: 28 days following initial treatment
The C-SSRS is a semi-structured interview to assess suicidal ideation and behavior. Based on responses, participants are categorized as Low Risk, Moderate Risk, or High Risk. An increase in risk level will be evaluated.
Time frame: 28 days following initial treatment
The MoCA is a neuropsychological screening test with scores ranging from 0-30 with lower scores suggesting higher cognitive impairment.
Contact information is provided by the study sponsor or research team.
SPIRE Therapeutics Inc.
Industry
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia: A Blinded Randomized Sham-Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04833465
Arthritis, Arthritis, Juvenile
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07398417
Fibromyalgia, Hyperalgesia
Glendale, Arizona, United States
View Trial DetailsNCT05962437
Fibromyalgia, Muscular Diseases
Barcelona, Spain
View Trial DetailsNCT05773482
Fibromyalgia, Muscular Diseases
Gainesville, Florida, United States
View Trial Details